Uncategorized – Page 6 – Policy & Medicine

Proposition 61 in California: Should We Be Worried?

FDA Raises Issue of Citizen Petitions

Life Science CEOs “Upbeat” About Industry Prospects

NPAs and DPAs – An Enforcement Loophole or Compliance Incentive?

Is Pricing the New Frontier?

The Debate Rages On: Should Clinical Trial Data Be Public?

FDA Criticized for Moving Too Slowly

ClinRegs Upgrades Are Here!

FDA Announces Dates for Public Hearing on Off-Label Communication Regulation

Novartis CEO Predicts Shift in Drug Pricing, Post-Election